TransCode Therapeutics (RNAZ) started dosing the first patient in the fourth cohort of its phase 1 cancer treatment trial.
Two more patients in the cohort are set to receive the TTX-MC138 "to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer," the company said Thursday in a statement.
"No significant safety or dose limiting toxicities have been reported," and additional patients are being evaluated for expanded enrollment, the company said.
Shares of the company rose 28% in after-hours trading.
Price: 0.6650, Change: +0.15, Percent Change: +27.88
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。